CEO Johan Falk comments on Asker's development:

2025 has been yet another good year with total adjusted EBITA growth of 17 per cent and a high level of activity. At the beginning of the year, Asker was listed on Nasdaq Stockholm - an important milestone in our journey. At the same time, our focus has remained the same: to create profitable growth through our "twin engine" model, both through organic growth and carefully selected acquisitions, thereby strengthening our leading position in medical products and solutions for healthcare in Europe. With 14 new acquisitions and entry into four new countries, we have taken several steps towards this goal while delivering on our financial promises to the market.

Learn more about Asker's growth journey and our commitment to supporting a more sustainable healthcare system in the Annual and Sustainability report 2025. The Report, including an ESEF version, is available at asker.com. A printed version can be ordered by sending an email to ir@asker.com.

For further information, please contact:
Emma Rheborg, Head of Communication Asker Healthcare Group
Phone: +46 73 313 62 17
E-mail: emma.rheborg@asker.com

This information is such that Asker Healthcare Group AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CEST on 16 April 2026.

Asker Healthcare Group is a partner to caregivers and patients across Europe providing medical products and solutions. We build and acquire leading companies that together support the healthcare system to improve patient outcomes, reduce total cost of care and ensure a fair and sustainable value chain. We are a European healthcare group that combines the entrepreneurial drive of strong local companies, with the abilities and collected knowledge of a large group - driving progress in the healthcare sector. The group has more than 4 500 employees in 19 countries and revenues amounting to SEK 17 billion.